France· FR:65864619
NUCALA 100 mg, poudre pour solution injectable
A medicinal product containing mépolizumab, registered in France by GLAXOSMITHKLINE TRADING SERVICES (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉPOLIZUMAB
- Manufacturer
- GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009300383521 flacon(s) en verreEUR 917
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mépolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandNucala 100 mg powder for solution for injectionGlaxoSmithKline Trading Services Limited
- NetherlandsNucala 100 mg poeder voor oplossing voor injectieGlaxoSmithKline Trading Services Limited
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaOrifarm Oy
- BelgiumNucala 100 mgGlaxoSmithKline Trading Services
- SpainNUCALA 100 MG POLVO PARA SOLUCION INYECTABLEGlaxosmithkline Trading Services Limited
- United KingdomNucala 100mg powder for solution for injection vialsGlaxoSmithKline UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8964f1a7-b52c-4646-8de1-2e78b064550b GET /v1/drugs/8964f1a7-b52c-4646-8de1-2e78b064550b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65864619",
"date_amm": "2015-12-02",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/15/1043",
"substance": "MÉPOLIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "poudre pour solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about mépolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.